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Recommended counseling for newly diagnosed chronic
hepatitis B virus (HBV) patients (i.e., hepatitis B surface anti-
gen [HBsAg]-positive for >6 months) includes education
regarding measures to minimize the risk of inadvertent HBV
transmission and promotion of healthy lifestyle habits.1,2 In
addition, a review of the patient’s current and past medical
history, HBV replication status, and liver disease severity
allows one to better estimate the risk of developing progres-
sive liver disease and hepatocellular carcinoma (HCC). These
data also help the clinician determine the need and type of
potential antiviral therapy and subsequent frequency and
type of disease monitoring.
Recommended Testing for Patients with
Chronic HBV
The physical examination in chronic HBV patients should
include an assessment for spider angioma, gynecomastia, and
splenomegaly, which are indicative of more advanced liver
disease. An assessment of the route (vertical versus horizon-
tal) and duration of infection, family history of cirrhosis and
HCC, alcohol and smoking habits, and current medication
and herbal product use should be undertaken (Table 1).
Although prothrombin time and bilirubin are normal in
most outpatients with chronic HBV, serial assessment of
serum aminotransferase (i.e., aspartate aminotransferase and
alanine aminotransferase [ALT]) levels can help determine
the current status of infection. In addition, a complete blood
count can help detect thrombocytopenia, which is an early
marker of portal hypertension. Chronic HBV patients should
be screened for concomitant hepatitis C virus, hepatitis D vi-
rus, and human immunodeficiency virus coinfection. Finally,
a baseline serum alpha-fetoprotein level and liver ultrasound
is recommended to screen for early stage HCC, radiographic
stigmata of cirrhosis, and other causes of liver disease.2
HBV Replication Markers and Disease
States
Laboratory markers of HBV replication include serum hep-
atitis B e antigen (HBeAg), anti-HBe, and quantitative HBV
DNA levels. Most HBV DNA assays are based on polymerase
chain reaction amplification with a lower limit of detection
of 10 to 50 IU/mL and a 4 to 5 log 10 dynamic range, while
assays using real-time polymerase chain reaction have
improved sensitivity and have a greater dynamic range (8-9
log10). Quantification of HBV DNA at initial diagnosis and
periodically thereafter in conjunction with serum ALT levels
obtained on three or more occasions can help categorize dis-
ease stage and guide antiviral treatment decisions (Fig. 1).
For example, immune tolerant patients that are HBeAg-posi-
tive with persistently high HBV DNA (>106 IU/mL) but nor-
mal ALT levels can defer antiviral therapy and be observed
with serial laboratory measurements. In contrast, immune
active HBeAg-positive patients with serum ALT levels persis-
tently >2 times the upper limit of normal (ULN) and HBV
DNA >20,000 IU/mL and HBeAg-negative patients with sim-
ilar ALT elevations and HBV DNA >2,000 IU/mL should be
considered for immediate antiviral therapy.2 After spontane-
ous HBeAg seroconversion to anti-HBe positivity, most inac-
tive carriers remain HBeAg-negative with low or undetectable
HBV DNA and normal or near normal serum ALT levels.
However, up to 30% of these patients may develop a sponta-
neous disease reactivation that requires antiviral therapy,
highlighting the need for indefinite laboratory and clinical
monitoring of all untreated chronic HBV patients.3
HBV Genotypes and Precore/Core
Promoter Variants
There are eight HBV genotypes labeled A through H that
differ in their nucleotide sequence throughout the HBV ge-
nome (Table 2).4 In one multicenter study of 694 patients in
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the United States, a broad distribution of HBV genotypes
was reported with genotypes A (35%) and D (10%), identi-
fied mostly in Caucasians and African Americans, whereas
genotypes B (22%) and C (31%) predominated in Asian
Americans.5 HBV genotypes may play an important role in
disease progression and potential response to interferon
(IFN) therapy. For example, Asian patients with HBV geno-
type B have earlier spontaneous HBeAg seroconversion and a
better response to IFN therapy compared with patients with
genotype C.6 In addition, the rate of disease progression and
lifetime risk of HCC appears to be greater with untreated
HBV genotype C > B.7 Similarly, Caucasian HBV patients
with genotype A are most responsive to IFN therapy, with a
40% to 50% likelihood of HBeAg seroconversion. However,
HBV genotypes are not associated with the likelihood of
response to oral antiviral agents. Therefore, most experts do
not recommend testing for HBV genotype in routine clinical
practice unless IFN therapy is being considered.
Patients with active and inactive HBeAg-negative liver dis-
ease frequently harbor viral variants that lead to reduced
expression of HBeAg in the serum.8 Precore variants that arise
due to a point mutation at G1896A in the precore region and
core promoter variants are frequently detected during sponta-
neous and treatment-induced HBeAg seroconversion. One
large study suggested that the presence of core promoter and
precore variants may increase the risk of HCC among
untreated Taiwanese men with long-standing chronic HBV.7
Although commercial assays are available, most experts do
not recommend testing for precore and core promoter variants
due to their dynamic status and uncertain clinical significance.
Quantitative HBsAg Levels
Quantitative HBsAg levels are being studied in relationship
to the natural history of chronic HBV and response to antivi-
ral therapy.9 Serum quantitative HBsAg levels largely reflect
the extent of host immune control over HBV replication.
The dynamic range of available HBsAg assays vary from 0.1
TABLE 1: Initial and Recommended Follow-up of Chronic HBV Patients
Initial evaluation
History and physical examination
Education to reduce transmission
Test/vaccinate household and sexual contacts
Minimize alcohol and smoking
Family history of HCC/cirrhosis
Assess body mass index
Laboratory tests
Serum AST/ALT, albumin, bilirubin, INR, complete blood count, platelet
count
HBeAg, anti-HBe, quantitative HBV DNA level
Exclude HCV, HDV, HIV coinfection
Serum AFP and liver ultrasound





Balanced diet and exercise to reduce insulin resistance/hepatic steatosis
Acetaminophen analgesics <4 g/day preferred over NSAIDs/aspirin




Normal ALT, HBV DNA >106 IU/mL
No immediate therapy
Untreated follow-up†
ALT every 3-6 months, then every 6 months
HBV DNA every 6 months
Immune active (HBeAg-positive)
Increased ALT, HBV DNA >2  104 IU/mL
Antiviral recommended
Untreated follow-up†
ALT and HBV DNA every 3-4 months
Immune active (HBeAg-negative)
Increased ALT, HBV DNA >2  103 IU/mL
Antiviral recommended
Untreated follow-up†
ALT and HBV DNA every 3-4 months
Inactive carrier (HBeAg-negative)
Normal or near normal ALT, HBV DNA low or undetectable
No immediate therapy
Untreated follow-up†
ALT and HBV DNA every 6-12 months
Treat if reactivation/disease flare detected
Abbreviations: AST, aspartate aminotransferase; EGD, esophagogastroduo-
denoscopy; HAV, hepatitis A virus; HCV, hepatitis C virus; HDV, hepatitis D
virus; HIV, human immunodeficiency virus; INR, international normalized
ratio.
*Disease state categorization should be based on three or more determi-
nations of serum ALT and HBV DNA levels over time.
†Obtain liver biopsy if uncertain, HCC surveillance per American Associa-
tion for the Study of Liver Diseases guidelines.2
FIGURE 1. Subjects with vertically acquired HBV typically are HBeAg-posi-
tive with persistently high serum HBV DNA but normal serum ALT levels for
several decades in the immune tolerant phase of infection. In young adulthood,
the host immune response tries to clear infected hepatocytes, which typically
results in a fluctuating serum ALT and HBV DNA level and HBeAg seroconver-
sion at a rate of 5% to 15% per year. HBeAg-positive and HBeAg-negative sub-
jects in the immune active phase of infection should be considered for antiviral
therapy to control HBV replication and reduce the risk of ongoing liver injury.
Most inactive carriers have a low to undetectable HBV DNA level and normal
or near normal serum ALT level. However, up to 30% may spontaneously reac-
tivate with or without HBeAg seroreversion and should be considered for treat-
ment to prevent further liver injury.
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to 1,000 IU/mL with serial dilutions possible from high titer
samples. Quantitative HBsAg levels correlate positively with
quantitative HBV DNA levels, and the correlation appears to
be more consistent in HBeAg-positive patients compared
with HBeAg-negative patients and inactive carriers. Retro-
spective studies suggest that lower baseline HBsAg levels in
untreated patients are associated with a higher rate of spon-
taneous HBsAg seroconversion and lower risk of HCC. Base-
line and on-treatment changes in HBsAg levels also may
prove to be a more reliable and sensitive predictor of sus-
tained response to IFN and oral antiviral therapy. However,
additional prospective studies that account for HBV geno-
type, HBV DNA level, and HBeAg status are needed to deter-
mine the role of HBsAg quantification in individualizing the
type and duration of treatment for chronic HBV.
Liver Biopsy and Noninvasive Staging
Methods
A liver biopsy in a patient with viral hepatitis provides im-
portant objective information on the severity of liver inflam-
mation as well as the stage of fibrosis. A liver biopsy can also
help identify concomitant disease processes such as hepatic
steatosis or steatohepatitis, which may increase the risk of liver
disease progression. Therefore, a liver biopsy may influence
the decision to treat a patient if more disease is noted than
suspected based on serum ALT and HBV DNA levels. In addi-
tion, because the risk of HCC and disease progression is
markedly higher in patients with bridging fibrosis and cirrho-
sis, monitoring and surveillance strategies may be altered.
However, it should be noted that most experts do not believe
that a liver biopsy is required prior to initiating antiviral ther-
apy unless there is clinical uncertainty regarding the severity
of liver disease. In addition, the limitations of liver biopsy
with regard to understaging hepatic fibrosis, sampling artifact,
and the procedural risk need to be considered.
Panels of serum fibrosis markers that reflect the extent of
hepatic fibrogenesis, fibrolysis, and liver apoptosis have been
proposed to noninvasively assess disease stage in chronic
HBV.10 However, their specificity and reliability may be
more limited in chronic HBV patients that frequently experi-
ence bursts of viral replication and liver necroinflammation
that can lead to false positive test results. Liver elastography
is a new noninvasive imaging modality wherein an external
transducer is placed against the right costal margin and the
speed of shear wave propagation reflects the extent of liver
stiffness that is proportional to the extent of hepatic fibro-
sis.11 Studies of liver elastography in chronic HBV patients
have demonstrated a good positive predictive value for detec-
tion of cirrhosis, but the presence of high serum ALT can
lead to false positive test results. In particular, chronic HBV
patients with a spontaneous surge in viral replication (high
HBV DNA) and liver necroinflammation (high serum ALT)
may have transient increases in liver stiffness that reflect
inflammation rather than fibrosis. Furthermore, measurement
of liver elastography can be technically difficult and less
accurate in overweight and obese patients. Magnetic reso-
nance elastography is another promising modality that sam-
ples a larger volume of tissue but requires further study.
Conclusions
All newly diagnosed chronic HBV patients should undergo
a complete history, physical assessment, and laboratory assess-
ment in an effort to assess the severity of liver disease and
potential need for antiviral therapy. Counseling to reduce
transmission and maintaining a healthy lifestyle are recom-
mended to minimize the influence of environmental cofactors
associated with liver disease progression. Markers of HBV rep-
lication (HBeAg, HBV DNA) along with serum ALT levels
should be obtained initially and periodically thereafter to
assess the state of HBV infection. A liver ultrasound is recom-
mended in all newly diagnosed chronic HBV patients to assess
for unsuspected liver masses, splenomegaly, and a nodular
liver suggestive of advanced fibrosis or portal hypertension,
which would influence decisions regarding treatment and
monitoring. In addition, serial serum alpha-fetoprotein and
ultrasound imaging is recommended for chronic HBV patients
at increased risk of developing HCC based upon their disease
state, demographic features, and medical history. Newer




Location Clinical SignificancePC BCP
A Low High North America, Europe, Central Africa Highest response to IFN
B High Low China, Japan, Korea, Asia Earlier HBeAg seroconversion; increased IFN response
compared with genotype C
C Low High China, Japan, Korea, Asia Delayed HBeAg seroconversion; increased risk of HCC
D High High The Mediterranean, Middle East, South Asia Most are HBeAg-negative
E ND ND West Africa
F Low ND South and Central America
G High ND United States, France
H ND ND Mexico, South America
Abbreviations: BCP, basal core promoter; ND, not described; PC, precore.
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noninvasive modalities such as liver elastography may play a
future role in assessing disease severity, but liver biopsy is cur-
rently recommended in cases of diagnostic uncertainty.
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